Abstract by Andy Bennett
Chemistry and Biochemistry
Identifying Gender Specific Biomarkers for Alzheimer’s Disease in Serum Using a LCMS Approach
Alzheimer’s Disease (AD) is the 6th leading cause of death in the U.S., killing more people than prostate and breast cancer combined. There are roughly 5.8 million people living with this disease and it is projected that those numbers will rise to 14 million by 2050. There is no cure for AD and there currently is no biochemical way to diagnose AD. Our research builds on a discovery study conducted at BYU where marked differences were seen in the abundances of certain molecules in AD patients and age/gender matched controls. Our project seeks to build upon this discovery and confirm the identity of novel biomarkers that can be used for pre-symptomatic screenings and diagnostic tests. This information can lead to a better understanding of AD pathology as well as facilitate better organized, focused and cheaper drug trials. This will in turn hopefully hasten the discovery of a cure.